{"nctId":"NCT00765817","briefTitle":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","startDateStruct":{"date":"2008-10"},"conditions":["Type 2 Diabetes"],"count":261,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide"]}],"interventions":[{"name":"placebo","otherNames":[]},{"name":"exenatide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes.\n* Have been taking insulin glargine at a dose of ≥20 units/day for at least 3 months before entering the study.\n\nHave been taking insulin glargine alone or in combination with one of the following for at least 3 months before entering the study:\n\n1. metformin (stable dose for 6 weeks)\n2. pioglitazone (stable dose for 6 weeks)\n3. a combination of metformin and pioglitazone (stable dose for 6 weeks)\n\n   * Have HbA1C between 7.1% and 10.5%, inclusive.\n   * Have a body mass index (BMI) ≤45 kg/m2.\n   * Have a history of stable body weight (not varying by \\>5% for at least 3 months prior to screening).\n\nExclusion Criteria:\n\n* Have taken medications to lower blood sugar other than insulin glargine, pioglitazone, or metformin in the 3 months before entering the study for more than a 1-week period, or within 1 week of entering the study.\n* Have had more than one episode of major (severe) hypoglycemia in the 6 months before entering the study.\n* Are pregnant or intend to become pregnant during the study or are sexually active women not actively practicing birth control.\n* Women who are breastfeeding.\n* Have any significant diseases of the blood, heart, kidney, gastrointestinal system, or other significant diseases such as cancer.\n* Have had a kidney transplant or are currently on kidney dialysis.\n* Have a cancer that's never been treated, that's currently being treated, or that was diagnosed within the last 5 years.\n* Have had a bad reaction to exenatide in the past or have a condition that is not recommended to be exposed to exenatide or any of exenatide's other ingredients.\n* Have used a drug for weight loss in the 3 months before entering the study for more than a 1-week period, or within 1 month of entering the study.\n* Are currently on a weight-loss program or have been on one within 3 months of entering the study.\n* Have had a blood transfusion or severe blood loss within 3 months of entering the study.\n* Are taking systemic glucocorticoids or have received systemic glucocorticoids within 8 weeks of entering the study.\n* Have an irregular sleep cycle (for example, sleeping during the day and working during the night).\n* Have a history of pancreatitis.\n* Have received treatment with an experimental drug within 30 days of entering the study.\n* If on metformin, have a condition that is not recommended to be exposed to metformin, or any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis.\n* If on metformin, have had a radiologic contrast study performed within 48 hours of entering the study.\n* If on pioglitazone, have a condition that is not recommended to be exposed to pioglitazone, including congestive heart failure, or are taking pioglitazone at a dose that is not approved for use with insulin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Hemoglobin (HbA1c)","description":"Change in HbA1c from baseline following 30 weeks of therapy (i.e., HbA1c at week 30 minus HbA1c at baseline). Unit of measure is percent of hemoglobin that is glycosylated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":"0.09"},{"groupId":"OG001","value":"-1.00","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving HbA1c <=7%","description":"Percentage of patients in each arm who had HbA1c \\>7% at baseline and had HbA1c \\<=7% at week 30 (percentage = \\[number of subjects with HbA1c \\<=7% at week 30 divided by number of subjects with HbA1c \\>7% at baseline\\] \\* 100%).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving HbA1c <=6.5%","description":"Percentage of patients in each arm who had HbA1c \\>6.5% at baseline and had HbA1c \\<=6.5% at week 30 (percentage = \\[number of subjects with HbA1c \\<=6.5% at week 30 divided by number of subjects with HbA1c \\>6.5% at baseline\\] \\* 100%).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Glucose","description":"Change in fasting serum glucose following 30 weeks of therapy (i.e., fasting serum glucose at week 30 minus fasting serum glucose at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"0.2"},{"groupId":"OG001","value":"-0.87","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in 7-point Self-monitored Blood Glucose (SMBG) Profile","description":"Change in 7-point (pre-breakfast, 2 hour post-breakfast, pre-lunch, 2 hour post-lunch, pre-dinner, 2 hour post-dinner, 0300 hours) SMBG profile from baseline to week 30 (change = blood glucose value at week 30 minus blood glucose value at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.89","spread":"0.2"},{"groupId":"OG001","value":"8.27","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"0.1"},{"groupId":"OG001","value":"-1.48","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.89","spread":"0.2"},{"groupId":"OG001","value":"11.82","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.56","spread":"0.2"},{"groupId":"OG001","value":"-1.72","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.95","spread":"0.2"},{"groupId":"OG001","value":"9.77","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.23","spread":"0.2"},{"groupId":"OG001","value":"-1.15","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.35","spread":"0.2"},{"groupId":"OG001","value":"11.70","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.74","spread":"0.2"},{"groupId":"OG001","value":"-1.38","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.85","spread":"0.2"},{"groupId":"OG001","value":"9.99","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.25","spread":"0.2"},{"groupId":"OG001","value":"-1.33","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.03","spread":"0.3"},{"groupId":"OG001","value":"11.86","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.87","spread":"0.2"},{"groupId":"OG001","value":"-1.34","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.95","spread":"0.2"},{"groupId":"OG001","value":"9.20","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.27","spread":"0.2"},{"groupId":"OG001","value":"-1.48","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol","description":"Change in total cholesterol following 30 weeks of therapy (i.e., total cholesterol at week 30 minus total cholesterol at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.08"},{"groupId":"OG001","value":"-0.02","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change in Low Density Lipoprotein (LDL) Cholesterol","description":"Change in LDL cholesterol following 30 weeks of therapy (i.e., LDL cholesterol at week 30 minus LDL cholesterol at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.07"},{"groupId":"OG001","value":"-0.00","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change in High Density Lipoprotein (HDL) Cholesterol","description":"Change in HDL cholesterol following 30 weeks of therapy (i.e., HDL cholesterol at week 30 minus HDL cholesterol at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.02"},{"groupId":"OG001","value":"0.00","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides","description":"Change in triglycerides following 30 weeks of therapy (i.e., triglycerides at week 30 minus triglycerides at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.09"},{"groupId":"OG001","value":"-0.03","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight following 30 weeks of therapy (i.e., body weight at week 30 minus body weight at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.78","spread":"0.3"},{"groupId":"OG001","value":"0.96","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Change in waist circumference following 30 weeks of therapy (i.e., waist circumference at week 30 minus waist circumference at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"0.52"},{"groupId":"OG001","value":"-0.25","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Change in Daily Insulin Dose","description":"Change in daily insulin dose following 30 weeks of therapy (i.e., daily insulin dose at week 30 minus daily insulin dose at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.19","spread":"2.02"},{"groupId":"OG001","value":"19.71","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Change in Daily Insulin Dose (on a Per Body Weight Basis)","description":"Change in daily insulin dose per kilogram (kg) following 30 weeks of therapy (i.e., daily insulin dose per kg at week 30 minus daily insulin dose per kg at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.02"},{"groupId":"OG001","value":"0.20","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (SBP)","description":"Change in SBP following 30 weeks of therapy (i.e., SBP at week 30 minus SBP at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.74","spread":"1.2"},{"groupId":"OG001","value":"1.71","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure (DBP)","description":"Change in DBP following 30 weeks of therapy (i.e., DBP at week 30 minus DBP at baseline)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"0.6"},{"groupId":"OG001","value":"1.69","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Minor Hypoglycemia Rate Per Year","description":"Number of minor hypoglycemia events experienced per subject per year. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose \\<3.0 mmol/L (54 mg/dL).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"5.94"},{"groupId":"OG001","value":"1.55","spread":"4.79"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Experiencing Minor Hypoglycemia","description":"Percentage of subjects in each arm experiencing at least one episode of minor hypoglycemia at any point during the study. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose \\<3.0 mmol/L (54 mg/dL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"28.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":137},"commonTop":["Nausea","Diarrhea","Vomiting","Headache","Upper Respiratory Tract Infection"]}}}